**SERA ENDOCAN AS A PREDICTIVE BIOMARKER OF CARDIOVASCULAR RISK IN OBESE PEDIATRIC PATIENTS**

S. CURATOLA1, G. MANDRAFFINO2, C. MORACE2, M. SCURUCHI2, AE. SERRANO2, A. TROPEANO1, M. WASNIEWSKA1, M. VALENZISE1

1. Department of Human Pathology of Adulthood and Childhood, University of Messina, Messina, Italy
2. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

**INTRODUCTION**

Endocan is a soluble dermatan sulfate proteoglycan, composed of 165 amino acid core protein, expressed and secreted by endothelial cells of dermal microcirculation, coronary, pulmonary arteries, and capillaries from adipose tissue. It plays an important role in the pathogenesis of vascular disorders, inflammation, and neangiogenesis. Endocan biosynthesis is upregulated by inflammatory cytokines (TNF-α, IL-1, TGF-β1, VEGF, EGF, and FGF-2); conversely, it is downregulated by INF-γ and insulin level. Endocan is a valid marker of endothelial cell damage in systemic inflammation, obesity, and cardiovascular diseases, and could be linked to the severity and outcomes of these disorders.

**AIM**

Aims of our study are the following:

a) to evaluate the use of endocan serum levels as an indicator of endothelial damage in children and adolescents with high BMI;

b) to identify its possible correlation with other metabolic indices.

**METHOD**

The study included 19 patients with obesity (10 males, 9 females), aged between 2-18 years (mean age 11.94±6.52), screened at the Pediatric Endocrinology Unit of Messina (Italy) from October 2018 to May 2020. We assessed weight, height, and BMI, and measured levels of endocan, total cholesterol, HDL-C, LDL-C, triglycerides, blood glucose, and insulin. Abdomen ultrasound was also performed.

**RESULTS**

The results, compared with healthy control group, have shown upraised endocan serum levels in children with high BMI (2.03±1.55 vs 0.82±0.14 ng/mL, p <0.001); demonstrating a positive correlation trend between endocan and BMI (r = 0.13). Furthermore, endocan serum levels were significantly correlated to fasting insulin levels (p = 0.047) and HOMA-IR (p = 0.072). These findings confirm the linkage between endothelial damage and insulin resistance in obese children (fig1). Instead, we did not found any association between endocan and lipid profile (LDL-C: p = 0.218; HDL-C: p = 0.684; TG: p = 0.342), nor with fasting blood glucose value (p = 0.926). We also performed abdomen ultrasound, revealing a correlation with steatosis and with its grade (p = 0.008, p = 0.088, respectively); despite not raising statistically significant results, given the small sample size, indeed only 12 children underwent ultrasound (fig2).

**CONCLUSIONS**

We can assume that endocan could be used, as a biomarker, also in children with obesity and that could be a valid predictor, in order to stratify the future cardiovascular risk in adulthood.

**REFERENCES**

- Sevket Balta, Dimitri P. Mikhailidis, Saït Demirkol, Cengiz Ozturk, Teryel Ceyk, Atilla Iyisoy: Endocan: a Novel Inflammatory Indicator in Cardiovascular Disease, Atherosclerosis. 2015; 245: 10-16

**ACKNOWLEDGEMENTS**

None

**CONTACT INFORMATION**

Dr. S. Curatola, MD, Department of Human Pathology in Adulthood and Childhood, University of Messina, via Consolare Valeria, 98124 Messina (Italy).

Tel: +39 3481546277

E-mail: curatolaselenia85@gmail.com

**REFERENCES**

- Sevket Balta, Dimitri P. Mikhailidis, Saït Demirkol, Cengiz Ozturk, Teryel Ceyk, Atilla Iyisoy: Endocan: a Novel Inflammatory Indicator in Cardiovascular Disease, Atherosclerosis. 2015; 245: 10-16